Artificial intelligence technology has tripled the number of UK stroke patients recovering to a point where they can perform daily activities, according to new research released on Tuesday. Early stage analysis of over 111,000 suspected stroke patients whose care included use of the technology found it reduced the time between being seen by a doctor and treatment beginning by over 60 minutes, leading to improved results. The proportion who were able to resume day-to-day activities increased from 16 to 48 percent, the analysis of the Brainomix e-Stroke imaging platform found. The technology, developed by the UK's med-tech solution firm Brainomix, is being used across 11 stroke treatment networks in the UK's state-funded National Health Service (NHS) to diagnose strokes and determine the best treatment. The platform helps doctors in the interpretation of brain scans and allows them to share the images with specialists worldwide who can access them remotely.

Ipswich Hospital has seen benefits to its stroke pathway thanks to a strategic tech partnership between Visionable and AI-powered medtech solutions company Brainomix. The partnership is combining Visionable's virtual healthcare collaboration platform with Brainomix's e-Stroke imaging software. The collaboration is saving time, reducing clinicians' workload and supporting improved outcomes for patients. The benefit of combining these two technologies has already been felt at Ipswich Hospital. Recent performance metrics have confirmed that Ipswich Hospital is delivering best-in-class service.

The AI-powered medtech solutions company, Brainomix, has been awarded the national tender in Hungary to deploy its AI stroke imaging software across all stroke centers in Hungary as part of the National Institute for Health Development initiative to improve stroke care. Awarded following a competitive process, the 5-year program is funded under the EU4Health programme and is the first time that a single stroke AI imaging platform will be deployed across an entire country. This latest tender will build upon an earlier EU grant that had funded the installation of Brainomix's flagship e-Stroke platform in 10 hospitals in and around the Hungarian city of Pécs. It will enable e-Stroke to be deployed across the remaining 28 stroke centres in Hungary's national healthcare system, with the support of eRAD, who will be serving as a technological partner. The initiative to use AI to improve stroke care and patient outcomes for the benefit of all stroke patients in Hungary was driven by world leading neuroscientist, Prof Dr István Szikora of the National Institute of Mental Health, Neurology and Neurosurgery, (OMIII) in Budapest, which will serve as the national stroke centre with full oversight for the program.

Brainomix – the AI-powered MedTech solutions company – and Bridge Biotherapeutics, a clinical-stage biotechnology company focused on developing novel drugs for cancer, fibrosis and inflammation, have announced a new partnership. The collaboration will deliver quantitative imaging biomarker analysis within the phase 2 study of novel autotaxin inhibitor BBT-877, which has been designed to evaluate the safety, tolerability and efficacy in idiopathic pulmonary fibrosis (IPF). Under the partnership, Brainomix will leverage its e-ILD technology – automated artificial intelligence software – which has been trained to process high resolution chest CT data in patients with interstitial lung diseases, including IPF and other conditions that cause progressive pulmonary fibrosis. Clinical trials in IPF commonly rely on serial physiological measurement of forced vital capacity as trial endpoints, which can be highly variable from day-to-day for any individual patient. Meanwhile, automated AI-powered quantitative imaging has the potential to significantly improve trial design, improve the chances of identifying a positive treatment response and accelerate the translation of new treatments into clinical practice.

Advanced technologies have caused a significant impact on the development of the healthcare industry. Artificial Intelligence (AI) and Machine Learning (ML) in particular, have allowed for significant breakthroughs in life science and healthcare research and treatments, whether that's automating critical but repetitive tasks to free up time for clinicians, through to automatic speech recognition for faster disease diagnosis, or the ability to create synthetic controls for clinical trials. But with 75 per cent of healthcare enterprises planning to execute an AI strategy next year, there's a far greater opportunity round the corner to further unleash its potential. Here, six experts from leading healthcare organisations including Brainomix, AiCure, HeartFlow, Cambridge Cognition, Oxford Brain Diagnostics and Zebra Medical Vision, share their views on what 2020 holds for the industry. "As highlighted earlier this year, the NHS aims to become a world leader in AI and machine learning in the next five years. In 2020, we expect to see this become more apparent in practical terms with, AI technologies becoming the predominant driving force behind imaging diagnostics. With around 780,000 people suffering a stroke each year in Europe, and 7.4 million people living with heart and circulatory diseases in the UK, it is imperative we find ways to reduce the burden on healthcare organisations and improve time to disease detection. The number of MRI and CT scans for example is already on the rise, and AI has the ability to read scans as accurately as an expert physician. Utilising these new technologies to review scans for any disease can reduce patient wait time and ease the burden on medical staff. There will be greater recognition next year of the value of AI in augmenting human performance."